Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorec... ( Results presented at American Society...)

Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer

Date:6/3/2008

Results presented at American Society of Clinical Oncology meeting indicate

CPX-1 improved clinical outcomes compared to historical data.

PRINCETON, N.J., June 3 /PRNewswire/ -- Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex(TM) technology. The results were presented in a poster presentation at the American Society of Clinical Oncology meeting in Chicago.

The CombiPlex(TM) drug ratio technology platform is a new approach which identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle and maintains the ratio in patients with the goal of improving clinical outcomes.

The multi-center, open-label, Phase 2 study had two arms, irinotecan-nave (IRI-naive) and irinotecan-refractory (IRI-refractory). IRI-naive patients had less than or equal to 2 prior regimens; one adjuvant/neoadjuvant and no more than 1 regimen for advanced disease. IRI-refractory patients had disease progression within 6 months of prior irinotecan-containing treatment and started CPX-1 treatment within 12 months of disease progression following irinotecan. Patients received 210 units/m2 of CPX-1 every two weeks.

Twenty-six patients were treated in the IRI-naive arm. The overall response rate (ORR) was 8 percent and the disease control rate (patients who achieved a response or stable disease) was 65 percent. Median progression- free survival (PFS) was 3.9 months. Six patients had a >6 month PFS. These data compare favorably to results published from other studies with irinotecan or an irinotecan-based regimen in this patient population which report an approximate 4 percent response rate and median PFS of 2.5 months.

Thirty-three patients were treated in the IRI-refractory arm. The disease control rate was 45
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
2. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
11. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

Post Your Comments:

(Date:6/17/2013)... June 17, 2013 The American Society of ... report on the effectiveness of medications for opioid ... FDA-approved drugs by many state governments and insurance ... drunk driving car crashes, an epidemic led by ... heroin. Yet, safe and effective medications to treat ...

(Date:6/17/2013)... As the Share Repurchase Resolution has been passed at ... Corporation, plc (NYSE: ELN ) has lapsed in ... Proceedings referred to below and any consequent decision of the ... to the extent that it would have been had it ... Repurchase Resolution being passed. There can be no assurance as ...

(Date:6/17/2013)... 17, 2013 Southern Research Institute today ... been selected by its Board of Directors to serve ... 8, 2013. (Photo: http://photos.prnewswire.com/prnh/20130617/DC33167 ... III, Ph.D., who served as president and CEO of ... retirement earlier this year after 34 years of service ...

[0] Effective Rx thwarted for deadly opiate epidemic [0] Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today [0] Southern Research Institute Names Arthur J. Tipton, Ph.D. President and CEO

... CITY, Calif., March 1, 2011 OncoMed Pharmaceuticals, Inc., ... cells, today announced the publication of preclinical data demonstrating ... reduces cancer stem cell frequency when administered alone or ... with or without KRAS mutations. This study was published ...

... March 1, 2011 Wako Diagnostics, a division of ... U.S. Food and Drug Administration (FDA) to market the ... prothrombin (DCP) in vitro diagnostic (IVD) tests ... intended for use by healthcare professionals as an aid ...

Cached Medicine Technology:OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 2 OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 3 OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 4 OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 5 Announcing 510(k) Clearance of a New Microfluidic-based IVD Test System, the uTASWako® i30 Immunoanalyzer, and AFP-L3 and DCP Assays for Liver Cancer Risk Assessment. 2

OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status Announcing 510(k) Clearance of a New Microfluidic-based IVD Test System, the uTASWako® i30 Immunoanalyzer, and AFP-L3 and DCP Assays for Liver Cancer Risk Assessment.

(Date:6/17/2013)... New York (PRWEB) June 18, 2013 ... has more physicians listed in New York magazine's ... In the latest survey, 209 NewYork-Presbyterian physicians from ... fortunate to have some of the nation's best ... J. Corwin, CEO of NewYork-Presbyterian Hospital. "We are ...

(Date:6/17/2013)... and Drug Administration (FDA) imposes new graphic warning ... First Amendment challenge if they depict health consequences ... evidence, says a Georgetown University Medical Center public ... warning labelswhich combine images with health warningsare a ... other countries, but the tobacco industry argues they ...

(Date:6/17/2013)... MA (PRWEB) June 17, 2013 Daimer ... robust steam cleaner equipment , such as expertly designed ... launched the KleenJet® Pro Plus 200S for apartment dwellers ... up to 310°F in 15 minutes and pressure levels ... effectively. The machine can be used to clean carpet ...

(Date:6/17/2013)... Bust’DD (pronounced ‘busted’), a new company that ... women with large busts, will soon launch their crowdfunding campaign ... understand the problem of ill-fitting bras and want to offer ... is to raise at least $25,000 to create their beta ... on a wide scale. , In order to kick off ...

(Date:6/17/2013)... (PRWEB) June 17, 2013 Today, ... stand-alone HRAs for small businesses . Zane Benefits, ... employer sponsored health benefits, is the leader in ... arrangements . , According to Zane Benefits’ website, ... Accounts or HRAs, offer small businesses an affordable ...

Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List 2 Health News:Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge? 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 3 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 2 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 3 Health News:Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses 2

[0] NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List [0] Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge?[0] Daimer Ships Vapor Steam Cleaner For Homeowners [0] Arizona Startup Bust’DD Looking to Start a BRAvolution [0] Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses

... , , , ... , the global leader in thin computing and client virtualization, today announced ... Smiles is a rapidly-growing company whose mission is to bring quality dental ... first office in 2002 in Atlanta, GA, the network has demonstrated substantial ...

... , , , ... Health, Inc. (Nasdaq: GHDX ) today announced that Kim ... Adams 29th Annual Global Growth Conference in Boston, on Thursday, August ... access the live and subsequently archived webcast of the presentation, visit ...

... , , , ... Aug. 6 CSC (NYSE: CSC ... company as a preferred provider to help member hospitals comply with the ... U.S. federal government stimulus package. Under the ARRA, hospitals will receive incentive ...

... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... of three MedCounselor consumer drug information modules for pharmacies and ... to take medications safely, assists in identifying unknown tablets or ... indispensable in helping to increase consumer compliance to their drug ...

... , KIBBUTZ SHAMIR, Israel, Aug. 6 Shamir ... to issue its second quarter of 2009 earnings results on Thursday, August ... at 11:00 A.M. EDT that morning. , , ... listen live, please go to www.kcsa.com approximately five ...

... Va., Aug. 6 Sunrise Senior Living, Inc. (NYSE: ... second quarter of 2009. Sunrise will host a conference call ... discuss the financial results. , , "Our restructuring ... expense controls. In recent weeks we have seen a modest lift ...

Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs)Genomic Health to Present at Canaccord Adams 29th Annual Global Growth Conference CSC to Help Georgia Hospital Association Members Achieve 'Meaningful Use' of Electronic Health Records Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results Sunrise Reports Financial Results for Second-Quarter 2009

... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...

200 L, Bulk, yellow Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....

... the Finntip Wide is designed especially for ... genomic DNA. This tip eliminates the mechanical ... excellent for use with extremely viscous liquids. ... of the orifice is 1.1 mm or ...

Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...

Medicine Products:

EcoPack D200 200 L Pipette Tip Finntip 250 Wide StrataTips Pipet Tips, Flat (1-200 l)